© JUN 2026 | IRE Journals | Volume 9 Issue 12 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I12-1719065

Good Products, Closed Doors: The Regulatory Market Entry Crisis Facing U.S. Pharmaceutical and Biomedical SMEs

OLUCHI BEATRICE ANEKE [1], DORCAS OKAYO OKOROAFOR [2], PATRICIA EBERE IWERUMOH [3]

[1] *Department of Business Administration University of Fairfax, USA*

[2] *Department of Biomedical Technology, University of Port Harcourt, Port Harcourt, Rivers State*

[3] *Faculty of Basic and Applied Biological sciences, Department of Public health, Ahmadu Bello University, Zaria*

Abstract- ***The United States remains a global leader in pharmaceutical and biomedical innovation, with small and medium-sized enterprises (SMEs) playing a critical role in developing advanced therapeutics, diagnostics, medical devices, and biotechnology solutions. Despite producing scientifically validated and globally competitive products, many of these firms struggle to achieve successful international market entry and sustained export growth. This article examines the regulatory market entry crisis facing U.S. pharmaceutical and biomedical SMEs, arguing that export underperformance is driven less by product quality and more by systemic regulatory barriers. Specifically, the paper explores how regulatory complexity, fragmented international approval systems, Harmonized System (HS) classification errors, and limited access to affordable compliance infrastructure constrain global market participation. While large pharmaceutical corporations possess dedicated regulatory affairs teams and extensive compliance resources, SMEs often lack the organizational capacity and financial resources necessary to navigate increasingly complex regulatory environments. The consequences extend beyond individual firms, limiting innovation commercialization, reducing export competitiveness, and weakening the global reach of U.S. biomedical innovation. The article further contends that these challenges represent not only a business concern but also a broader issue of national competitiveness, supply chain resilience, and economic security. To address this gap, the paper proposes the recognition of regulatory market entry strategy as a formal strategic discipline and advocates for scalable compliance solutions capable of improving export readiness among pharmaceutical and biomedical SMEs. Strengthening regulatory capabilities may enhance international market access, accelerate innovation diffusion, and reinforce the long-term competitiveness of the U.S. life sciences sector.***

Keywords: ***Biomedical Exports, Compliance Infrastructure, HS Classification, Pharmaceutical SMEs, Regulatory Market Entry.***

I. INTRODUCTION

1.1 U.S. Leadership in Pharmaceutical and Biomedical Innovation

The United States has long maintained a dominant position in pharmaceutical and biomedical innovation, serving as a global hub for the development of advanced therapeutics, biotechnology products, medical devices, diagnostics, and emerging healthcare technologies [1].

This leadership is supported not only by multinational pharmaceutical corporations but also by a dynamic ecosystem of small and medium-sized enterprises (SMEs) that play a critical role in translating scientific discoveries into commercially viable products. These firms are frequently responsible for pioneering innovations in areas such as precision medicine, biologics, digital health, molecular diagnostics, and next-generation medical technologies [2].

The economic and strategic significance of pharmaceutical and biomedical SMEs extends well beyond domestic markets. International expansion provides access to larger customer bases, diversified revenue streams, global research partnerships, and opportunities for accelerated commercialization. For many life science companies, exports are not simply a growth strategy but a commercial necessity.

Given the substantial costs associated with research and development, regulatory approval, and product commercialization, access to international markets often determines whether innovative products achieve sustainable market success. Consequently, export performance has become an increasingly important indicator of competitiveness within the U.S. life sciences sector [3,4].

1.2 The Export Paradox

Despite producing world-class products and operating within one of the most advanced innovation ecosystems in the world, many U.S. pharmaceutical and biomedical SMEs struggle to establish a meaningful presence in international markets. This reality presents a striking paradox. Firms that successfully navigate demanding domestic regulatory pathways, secure intellectual property protection, and develop scientifically validated products frequently encounter significant barriers when attempting to export those same products abroad [5].

Conventional explanations for export underperformance often focus on financing constraints, market competition, limited marketing capacity, or insufficient international business experience. While these factors undoubtedly influence export outcomes, they fail to fully explain why technologically sophisticated firms with proven products continue to experience persistent market entry failures. In practice, product excellence alone does not guarantee global commercial success.

Increasingly, the ability to navigate complex regulatory environments, comply with diverse international requirements, and manage trade-related obligations has become a determining factor in whether innovative firms successfully enter foreign markets [6].

The result is a growing disconnect between innovation capability and international market access. Many SMEs possess products that are technically competitive on a global scale but lack the regulatory infrastructure necessary to convert innovation into export success.

1.3 Problem Statement

A significant yet frequently overlooked driver of export failure among pharmaceutical and biomedical SMEs is the growing complexity of international regulatory systems. Unlike many other industries, life science exports operate within highly regulated environments characterized by extensive documentation requirements, product registration procedures, import licensing obligations, customs controls, quality assurance standards, and post-market compliance expectations. These requirements often vary substantially across jurisdictions, creating a fragmented and resource-intensive landscape for exporters.

Particularly problematic are challenges associated with Harmonized System (HS) classification, customs compliance, and regulatory market entry planning. Incorrect product classification can result in shipment delays, tariff disputes, customs inspections, licensing complications, and even market access restrictions. Regulatory requirements that appear administrative in nature frequently have direct commercial consequences, influencing market entry timelines, operational costs, and competitive positioning.

Large pharmaceutical corporations typically possess dedicated regulatory affairs departments, trade compliance specialists, legal teams, and international market access experts capable of managing these complexities. Pharmaceutical and biomedical SMEs, however, rarely have comparable resources. The cost of obtaining specialized regulatory expertise is often prohibitive, creating a compliance infrastructure gap that places smaller firms at a substantial disadvantage. Consequently, many SMEs encounter barriers that have little to do with product quality and much to do with their capacity to navigate increasingly complex regulatory environments.

1.4 Purpose of the Article

This article examines the regulatory market entry crisis confronting U.S. pharmaceutical and biomedical SMEs and investigates why many innovative firms fail to achieve sustainable export growth despite producing globally competitive products. Specifically, the paper explores how regulatory complexity, HS classification challenges,

and limited access to affordable compliance infrastructure contribute to international market entry failure.

Beyond identifying the causes of export underperformance, the article argues that the issue should not be viewed solely as a business or operational concern. The inability of innovative SMEs to access global markets has broader implications for national competitiveness, technological leadership, supply chain resilience, and economic security. As international competition within the life sciences sector intensifies, barriers that restrict the global reach of innovative firms may ultimately weaken the broader innovation ecosystem that underpins U.S. leadership in healthcare and biotechnology.

To address this challenge, the paper proposes the development of regulatory market entry strategy as a formal strategic discipline that integrates regulatory intelligence, trade compliance, market access planning, and risk management into export decision-making. In addition, it advocates for scalable compliance solutions capable of reducing barriers for SMEs and strengthening the international competitiveness of the U.S. pharmaceutical and biomedical sector.

II. RESEARCH ELABORATIONS

2.1 Understanding Regulatory Market Entry

International market access within the pharmaceutical and biomedical sectors is governed by far more than product quality, scientific innovation, or commercial demand. Before a product can reach foreign healthcare providers, distributors, hospitals, or patients, it must successfully navigate a complex framework of regulatory, trade, and compliance requirements. This process may be broadly defined as regulatory market entry the coordinated set of activities required to obtain lawful access to foreign markets through compliance with applicable regulatory, customs, trade, and product approval requirements [7].

Regulatory market entry differs fundamentally from product development. Product development focuses on scientific discovery, research and development, testing, manufacturing, and commercialization. Regulatory market entry, by contrast, focuses on obtaining legal permission to access and operate within target markets [8].

A product may be technologically advanced, clinically effective, and commercially viable, yet remain excluded from international markets if regulatory requirements are not properly addressed.

Historically, many firms have viewed regulatory compliance as a post-development administrative function rather than a strategic component of international expansion. However, in highly regulated industries such as pharmaceuticals and biomedical technologies, regulatory readiness has emerged as a prerequisite for export success [9].

Regulatory readiness encompasses the organizational capabilities required to understand foreign regulatory systems, manage compliance obligations, prepare documentation, classify products correctly, and anticipate market-specific requirements before export activities begin [10].

The growing importance of regulatory readiness reflects a broader shift in international trade. Competitive advantage is no longer determined solely by innovation and manufacturing excellence but increasingly by a firm's ability to navigate complex regulatory ecosystems [11,12].

As a result, regulatory market entry has become a strategic determinant of export performance, particularly for small and medium-sized enterprises operating with limited resources.

2.2 Regulatory Complexity in Global Pharmaceutical and Biomedical Trade

Among all sectors engaged in international trade, pharmaceuticals and biomedical products face some of the most demanding regulatory requirements. Unlike conventional consumer goods, these products directly affect human health and safety, prompting governments to impose extensive oversight mechanisms designed to ensure product quality, efficacy, traceability, and patient protection [13].

One major challenge stem from the fragmentation of global regulatory systems. Pharmaceutical and biomedical exporters must navigate a diverse landscape of regulatory authorities, each operating under different legal frameworks, approval standards, documentation requirements, and enforcement practices [14].

Requirements accepted in one jurisdiction may be insufficient in another, forcing exporters to adapt products and compliance strategies to individual markets.

Product registration procedures represent a particularly significant barrier. Many countries require extensive technical documentation, clinical evidence, manufacturing certifications, safety records, and quality assurance reports before granting market authorization. These procedures often involve lengthy review periods, repeated information requests, and substantial administrative costs [15].

Additional complexity arises from labeling regulations, packaging standards, language requirements, import permits, and post-market surveillance obligations. Manufacturers must ensure that product information, warnings, instructions, and certifications align precisely with local regulations. Even minor discrepancies can delay approvals or prevent market access entirely [16].

Quality and manufacturing compliance requirements further intensify these challenges. International markets frequently require evidence of adherence to Good Manufacturing Practice (GMP) standards, quality management systems, supply chain controls, and product traceability mechanisms. Maintaining compliance across multiple jurisdictions can impose substantial operational and financial burdens, particularly for smaller firms with limited regulatory infrastructure [17].

The cumulative effect of these requirements is a regulatory environment that favors organizations possessing extensive compliance resources while creating significant barriers for resource-constrained SMEs.

2.3 The Hidden Impact of HS Classification Errors

Although discussions of pharmaceutical exports often focus on regulatory approvals and product registrations, one of the most overlooked determinants of export success is accurate Harmonized System (HS) classification. The HS system serves as the international framework used by customs authorities worldwide to classify traded products for tariff, regulatory, and statistical purposes [9].

For pharmaceutical and biomedical products, classification can be particularly challenging. Advances in biotechnology, combination products, digital health technologies, diagnostic systems, and specialized medical devices have blurred traditional product categories. Consequently, determining the correct HS code often requires a sophisticated understanding of both product characteristics and international customs regulations [18].

Classification errors can trigger a range of commercial and regulatory consequences. Incorrect codes may result in inappropriate tariff assessments, customs inspections, licensing disputes, or non-compliance findings. Products may be delayed at ports of entry while authorities verify classifications, creating costly disruptions to supply chains and customer relationships.

Beyond operational delays, misclassification can expose firms to regulatory scrutiny and financial penalties. Repeated errors may damage credibility with customs authorities and trading partners, increasing future compliance risks. For SMEs attempting to establish themselves in international markets, such disruptions can undermine distributor confidence and erode market opportunities before commercial relationships are fully established [19].

Importantly, HS classification errors are often symptoms of a broader regulatory capability gap rather than isolated administrative mistakes. They illustrate how seemingly technical compliance issues can become significant barriers to international market entry.

2.4 The Compliance Infrastructure Gap

A defining characteristic of the pharmaceutical export landscape is the unequal distribution of compliance capabilities between large corporations and SMEs. While regulatory complexity affects all exporters, the capacity to manage these challenges varies considerably across organizations [20,21].

Large pharmaceutical corporations typically maintain extensive compliance infrastructures that include regulatory affairs departments, customs specialists, trade compliance officers, legal advisors, quality assurance professionals, and market access experts. These resources allow organizations to monitor regulatory changes, manage approval processes, conduct classification assessments, and respond rapidly to compliance challenges [13].

For SMEs, the situation is markedly different. Many firms operate with lean organizational structures focused primarily on research, product development, manufacturing, and commercialization. Dedicated compliance personnel are often absent, and regulatory responsibilities may be distributed among employees whose primary expertise lies outside trade and regulatory affairs [22].

Financial constraints further exacerbate this challenge. External regulatory consultants, customs advisors, and legal specialists can be prohibitively expensive for smaller firms, particularly during early stages of growth. Consequently, many SMEs enter international markets without sufficient compliance preparation or delay expansion altogether because of perceived regulatory uncertainty [23].

This disparity creates a compliance infrastructure gap in which market access is influenced not only by product quality but also by organizational capacity. Firms with comparable products may experience dramatically different export outcomes based solely on their ability to navigate regulatory requirements effectively [24].

The unequal distribution of regulatory and compliance resources represents one of the most significant structural disadvantages facing pharmaceutical and biomedical SMEs. As shown in Table 1, large pharmaceutical corporations possess extensive compliance infrastructures that allow them to absorb regulatory complexity, whereas SMEs often operate with limited expertise and constrained resources.

Table 1. Comparison of Export Compliance Capabilities: SMEs vs. Large Pharmaceutical Firms

Compliance Dimension	Pharmaceutical and Biomedical SMEs	Large Pharmaceutical Companies
Regulatory Affairs Personnel	Limited or absent dedicated staff	Specialized regulatory affairs departments
HS Classification Expertise	Often outsourced or unavailable	In-house customs and trade specialists
Compliance Budget	Restricted financial resources	Significant compliance investment capacity
Regulatory Intelligence	Limited monitoring of regulatory changes	Continuous global regulatory surveillance
Market Access Planning	Often reactive and project-based	Integrated strategic planning processes
Legal Support	External legal support when affordable	Dedicated legal and compliance teams
Documentation Management	Manual and resource-constrained	Advanced compliance management systems
Approval Process Experience	Limited international experience	Extensive multi-market experience
Risk Management Capacity	Reactive approach to compliance risks	Proactive risk assessment frameworks
Ability to Absorb Regulatory Delays	Low tolerance for delays and added costs	Greater operational and financial resilience

2.5 Why Good Products Still Fail Internationally

The persistent export challenges experienced by pharmaceutical and biomedical SMEs cannot be attributed to a single factor. Rather, they emerge from the interaction of multiple barriers that collectively undermine international market entry efforts.

Regulatory uncertainty remains one of the most significant obstacles. SMEs frequently struggle to interpret evolving requirements across multiple jurisdictions, creating uncertainty regarding approval pathways, documentation expectations, and compliance obligations [25].

Approval delays further compound these difficulties. Lengthy review processes can postpone product launches, increase operational costs, and reduce the commercial viability of export initiatives. For smaller firms operating with limited financial reserves, delayed market entry may threaten long-term sustainability [26].

Compliance costs represent another major challenge. Expenses associated with regulatory submissions, product registrations, certifications, legal reviews, and consulting services can consume substantial portions of organizational budgets. These costs often increase disproportionately as firms expand into multiple markets [27].

HS classification risks introduce additional uncertainty by exposing firms to customs disputes, shipment delays, and regulatory investigations. Even when products satisfy technical and clinical standards, classification errors can disrupt international operations.

Documentation requirements also impose considerable burdens. Exporters must manage large volumes of regulatory, technical, quality, and customs documentation while ensuring accuracy and consistency across jurisdictions.

Finally, many SMEs encounter market-entry missteps resulting from inadequate planning, insufficient regulatory intelligence, or incomplete understanding of target market requirements. Such errors frequently lead to delays, increased costs, and missed commercial opportunities [28].

Collectively, these barriers demonstrate that export failure is often a consequence of regulatory and compliance shortcomings rather than deficiencies in product quality or innovation.

The barriers discussed above rarely occur in isolation. Instead, pharmaceutical and biomedical SMEs frequently encounter multiple regulatory challenges simultaneously, creating cumulative obstacles to successful export market entry. Table 2 summarizes the major regulatory barriers affecting international expansion and their implications for export performance.

Table 2. Major Regulatory Barriers Affecting Pharmaceutical and Biomedical SME Exports

Regulatory Barrier	Description	Impact on SMEs	Export Consequence
Regulatory Complexity	Multiple and often conflicting international regulations	Difficulty interpreting requirements	Delayed market entry
Product Registration Requirements	Extensive documentation and approval processes	Increased administrative burden	Prolonged commercialization timelines
HS Classification Errors	Incorrect customs classification of products	Customs disputes and compliance risks	Shipment delays and financial losses
Labeling and Documentation Requirements	Country-specific packaging, language, and documentation rules	Frequent revisions and compliance costs	Product approval delays
Quality and Manufacturing	GMP and quality assurance obligations	Resource-intensive compliance management	Restricted market access

Compliance			
Import Licensing Requirements	Market-specific import permits and authorizations	Additional procedural complexity	Entry barriers in target markets
Regulatory Intelligence Gaps	Limited awareness of changing regulations	Inadequate preparation for foreign markets	Increased compliance failures
High Compliance Costs	Cost of consultants, legal support, and certifications	Financial strain on SMEs	Reduced export competitiveness

2.6 Economic Consequences for U.S. Pharmaceutical and Biomedical SMEs

The economic consequences of regulatory market entry failure extend far beyond individual export transactions. For pharmaceutical and biomedical SMEs, unsuccessful international expansion can limit growth opportunities, reduce revenue generation, and constrain long-term competitiveness [29].

Lost export revenue represents the most immediate consequence. Firms unable to access foreign markets forfeit opportunities to reach millions of potential customers and diversify income streams beyond domestic demand. This limitation is particularly significant for niche biomedical products whose commercial success may depend upon global market access [30].

Reduced international participation also weakens competitive positioning. Firms that fail to establish an early presence in emerging markets risk losing strategic advantages to foreign competitors capable of navigating regulatory systems more effectively.

The commercialization of innovation may likewise be delayed. Many biomedical products require substantial investment before reaching the market, and restricted export opportunities can reduce returns on research and development expenditures. Lower returns may subsequently discourage future innovation investment [31].

Perhaps most importantly, regulatory barriers can prevent SMEs from participating in rapidly expanding healthcare markets across Asia, Africa, Latin America, and the Middle East. Missed opportunities in these regions may limit the global impact of U.S. biomedical innovation while reducing the overall competitiveness of the sector.

2.7 Beyond Business: A National Competitiveness and Security Challenge

The challenges confronting pharmaceutical and biomedical SMEs should not be viewed solely through a commercial lens. Increasingly, they represent issues of national competitiveness, economic resilience, and strategic security.

Pharmaceutical exports contribute significantly to economic growth, technological leadership, and international influence. When innovative SMEs struggle to reach global markets, the broader national innovation ecosystem loses opportunities to translate scientific advancements into economic value [32].

The issue also has implications for supply chain resilience. A diverse and internationally competitive life sciences sector provides greater flexibility, redundancy, and adaptability during periods of disruption. Overreliance on a limited number of large corporations may increase vulnerabilities within critical healthcare supply chains.

Innovation leadership is similarly affected. SMEs frequently serve as sources of disruptive technologies and breakthrough discoveries. Barriers that restrict their international expansion may ultimately reduce the global reach and influence of U.S. innovation [33].

From an economic security perspective, enabling SMEs to participate effectively in international markets strengthens national competitiveness by expanding export capacity, supporting high-value employment, and reinforcing strategic industries essential to public health and technological advancement [34].

The challenges facing pharmaceutical and biomedical SMEs do not occur as isolated regulatory events.

© JUN 2026 | IRE Journals | Volume 9 Issue 12 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I12-1719065

Rather, they form a cumulative pathway in which regulatory complexity, compliance constraints, and market-access barriers progressively undermine export success. Figure 1 illustrates the sequence through which innovative products can fail to achieve international commercialization despite possessing strong scientific and commercial potential.

Figure 1. Conceptual model demonstrating how regulatory market-entry barriers progressively constrain export performance among pharmaceutical and biomedical SMEs. The framework highlights how compliance-related challenges can transform innovative and commercially viable products into unsuccessful export ventures despite their scientific and market potential.

As shown in Figure 1, export underperformance among pharmaceutical and biomedical SMEs is often the result of interconnected regulatory and compliance barriers that accumulate throughout the market-entry process. These findings underscore the need for a more structured and proactive approach to regulatory preparedness.

2.8 Establishing Regulatory Market Entry Strategy as a New Discipline

Given the growing influence of regulatory factors on export performance, there is a compelling case for recognizing regulatory market entry strategy as a distinct strategic discipline. Existing export frameworks often emphasize market selection, competitive positioning, and commercial partnerships while treating compliance as a secondary operational concern. In practice, however, regulatory readiness frequently determines whether market access is achieved at all.

Regulatory market entry strategy may be defined as the systematic integration of regulatory intelligence, compliance planning, market access assessment, risk management, and documentation readiness into international expansion decision-making.

Several components are central to this approach. Regulatory intelligence enables firms to monitor evolving requirements and identify emerging compliance risks. Export compliance planning establishes procedures for meeting customs and trade obligations.

HS classification management reduces the likelihood of costly classification errors and shipment disruptions. Market access assessment evaluates regulatory feasibility before significant investments are made. Risk management identifies potential barriers and mitigation strategies, while documentation readiness ensures that technical and regulatory information is available when needed [35].

To operationalize the concept of regulatory market entry strategy, a structured framework is required that integrates regulatory, compliance, and market-access capabilities into a coherent export readiness model. Figure 2 presents a Regulatory Market Entry Strategy Framework for pharmaceutical and biomedical exporters, illustrating how foundational regulatory competencies can strengthen organizational preparedness and ultimately improve international market-entry outcomes.

Together, these capabilities transform compliance from a reactive administrative function into a proactive strategic asset.

© JUN 2026 | IRE Journals | Volume 9 Issue 12 | ISSN: 2456-8880
DOI: https://doi.org/10.64388/IREV9I12-1719065

Figure 2. Regulatory Market Entry Strategy Framework for Enhancing Export Readiness Among Pharmaceutical and Biomedical SMEs. Conceptual framework illustrating how foundational regulatory capabilities support the development of regulatory preparedness, compliance infrastructure, market-access capability, and strategic export readiness. Together, these capabilities facilitate faster market entry, reduce compliance risks and costs, improve international competitiveness, and support sustainable export growth among pharmaceutical and biomedical SMEs.

As illustrated in Figure 2, successful international expansion requires more than regulatory compliance alone. Export success emerges from the integration of multiple strategic capabilities that collectively enhance regulatory preparedness and market-access readiness. By adopting a structured regulatory market entry strategy, pharmaceutical and biomedical SMEs can reduce compliance-related barriers, improve export performance, and strengthen their ability to compete in increasingly complex global markets.

2.9 Building Scalable Compliance Solutions for SMEs

Addressing the regulatory market entry crisis requires solutions that extend beyond individual firms. Because many SMEs lack the resources necessary to build comprehensive compliance infrastructures independently, scalable support mechanisms are essential.

One promising approach involves the development of shared compliance platforms that provide affordable access to regulatory guidance, classification tools, documentation templates, and market intelligence. Such platforms could reduce costs while increasing regulatory preparedness across the sector.

Regulatory support networks may also play an important role by connecting SMEs with compliance specialists, industry experts, and export advisors. These networks can facilitate knowledge sharing and improve access to specialized expertise [36].

Public-private partnerships represent another potential solution. Collaboration among government agencies, industry associations, academic institutions, and compliance providers could help expand regulatory support services while strengthening export readiness.

Targeted export assistance programs focused specifically on pharmaceutical and biomedical firms may further reduce barriers to international expansion. Finally, advances in digital compliance technologies, including automated classification systems, regulatory intelligence platforms, and artificial intelligence-driven compliance tools, offer opportunities to improve efficiency while lowering costs [37].

Collectively, these approaches can help bridge the compliance infrastructure gap and create a more accessible pathway to global market participation for innovative pharmaceutical and biomedical SMEs.

III. RESULTS AND FINDINGS

3.1 Major Findings

The analysis presented in this article reveals that export underperformance among U.S. pharmaceutical and biomedical SMEs is driven less by deficiencies in innovation and product quality than by systemic barriers associated with regulatory market entry. Across the literature on international trade, regulatory compliance, and market access, a consistent pattern emerges: firms that successfully develop globally competitive products often struggle to convert technological capability into international commercial success because of regulatory obstacles that disproportionately affect smaller enterprises [38].

Finding 1: Regulatory Complexity Is a Primary Driver of Export Failure

The first major finding is that regulatory complexity has become one of the most significant determinants of export success within the pharmaceutical and biomedical sectors. International market access requires firms to navigate diverse regulatory environments characterized by varying approval processes, product registration requirements, labeling standards, import controls, and quality assurance obligations. While these regulations serve important public health functions, their cumulative complexity creates substantial barriers for SMEs with limited regulatory expertise and resources [13].

Unlike larger firms that possess dedicated compliance infrastructures, SMEs frequently face difficulties interpreting and managing multiple regulatory frameworks simultaneously. As a result, regulatory challenges often delay market entry, increase operational costs, and discourage international expansion altogether. The evidence suggests that regulatory complexity is no longer a secondary business concern but a central factor shaping export outcomes [39].

Finding 2: HS Classification Errors Remain an Underrecognized Barrier

A second important finding is that HS classification errors represent a significant yet frequently overlooked source of export failure. Although product classification is often viewed as a technical customs requirement, its implications extend far beyond administrative compliance.

Pharmaceutical and biomedical products are increasingly complex, combining biological, chemical, digital, and technological components that may not fit neatly within traditional classification systems. Consequently, SMEs face elevated risks of misclassification, particularly when entering unfamiliar international markets [40].

Incorrect classification can trigger customs delays, tariff disputes, shipment holds, licensing complications, and regulatory investigations. These disruptions can undermine customer confidence, damage relationships with distributors, and increase export costs. The analysis indicates that HS classification should be recognized as a strategic market-entry issue rather than a routine documentation exercise [19].

Finding 3: The Compliance Infrastructure Gap Disadvantages SMEs

The third finding concerns the substantial disparity in compliance capabilities between SMEs and large pharmaceutical corporations. Large firms routinely employ regulatory affairs specialists, customs experts, legal advisors, quality assurance professionals, and market access teams dedicated to managing international compliance obligations. Such resources enable them to absorb regulatory complexity as a routine cost of doing business [20].

SMEs operate under markedly different conditions. Many lack specialized personnel, dedicated compliance budgets, or access to affordable regulatory expertise. Regulatory responsibilities are often assigned to employees whose primary roles lie outside compliance and international trade. Consequently, SMEs encounter greater uncertainty, higher relative compliance costs, and increased exposure to market-entry risks [41].

The evidence suggests that export performance is influenced not only by product quality but also by organizational access to compliance infrastructure. This creates structural disadvantages that limit the international competitiveness of otherwise innovative firms.

Finding 4: Export Failure Stems More from Market Entry Barriers Than Product Quality

Perhaps the most significant finding is that export failure among pharmaceutical and biomedical SMEs frequently originates from market-entry barriers rather than deficiencies in product quality. Many SMEs successfully navigate rigorous domestic development and approval processes, demonstrating high levels of scientific competence and technological capability. Yet these same firms often struggle to establish international market presence.

This discrepancy highlights the growing separation between innovation success and export success. Developing a high-quality product is no longer sufficient to guarantee global competitiveness. Instead, firms must also possess the regulatory

capabilities necessary to secure market access, maintain compliance, and manage international trade obligations [42].

The findings challenge traditional assumptions that weak export performance reflects inferior products or inadequate innovation. In many cases, products are fully capable of competing internationally, but the firms behind them lack the regulatory resources needed to reach global customers.

Finding 5: Current Support Mechanisms Remain Inadequate for SME Needs

The final finding is that existing support structures are insufficient to address the unique regulatory challenges facing pharmaceutical and biomedical SMEs. Although various export promotion initiatives, trade assistance programs, and regulatory guidance resources exist, many fail to provide the specialized support required for highly regulated life science industries.

Current programs often emphasize market development and trade promotion while providing limited assistance in areas such as regulatory intelligence, HS classification management, product registration strategy, and compliance planning. As a result, many SMEs continue to face significant barriers despite the availability of broader export assistance initiatives [29].

This finding highlights the need for more targeted interventions designed specifically to address regulatory market-entry challenges within the pharmaceutical and biomedical sectors.

3.2 Emerging Pattern

Collectively, these findings reveal a consistent and concerning pattern. The principal challenge confronting many U.S. pharmaceutical and biomedical SMEs is not the development of innovative products but the ability to successfully navigate the regulatory pathways required to commercialize those products internationally. As regulatory requirements become increasingly complex, the determinants of export success are shifting away from traditional measures of innovation and toward organizational regulatory capability [43].

A growing number of scientifically advanced products are effectively excluded from global markets not because they fail to meet clinical or technological standards, but because the firms responsible for them lack the regulatory infrastructure necessary to achieve market access. This phenomenon represents a significant inefficiency within the broader innovation ecosystem, where substantial investments in research and development fail to translate into international commercial opportunities [44].

The evidence further suggests that regulatory capability is emerging as a strategic competitive asset. Firms capable of managing regulatory complexity, classification requirements, compliance obligations, and market access planning are increasingly positioned to outperform competitors regardless of comparable levels of product innovation. Consequently, export success within the pharmaceutical and biomedical sectors is becoming as much a function of regulatory preparedness as scientific excellence [45].

This emerging pattern underscores the central argument of this article: good products are not necessarily failing because they lack quality, innovation, or market demand. Rather, they are being prevented from reaching global markets by regulatory barriers that disproportionately affect SMEs and that existing support systems have yet to adequately address.

IV. CONCLUSION

4.1 Summary of Key Insights

This article examined the persistent challenges confronting U.S. pharmaceutical and biomedical SMEs as they attempt to enter and compete within international markets. Despite producing innovative, scientifically advanced, and commercially viable products, many of these firms experience disproportionate difficulty achieving sustainable export growth. The analysis demonstrates that export underperformance is often not the result of weak products, insufficient innovation, or limited market demand. Rather, it reflects a broader regulatory market-entry crisis characterized by regulatory

complexity, HS classification challenges, compliance burdens, and unequal access to specialized expertise.

The findings indicate that international market access within the pharmaceutical and biomedical sectors is increasingly determined by regulatory capability rather than product quality alone. While large pharmaceutical corporations possess the institutional resources necessary to navigate complex regulatory systems, SMEs frequently lack the infrastructure required to manage approval requirements, compliance obligations, customs procedures, and market-access risks effectively. This compliance infrastructure gap creates structural barriers that prevent many innovative firms from translating scientific achievements into international commercial success.

The central insight emerging from this study is that export failure among pharmaceutical and biomedical SMEs should be understood primarily as a market-entry problem rather than a product-development problem. In many cases, globally competitive products are unable to reach international customers because the firms producing them lack the regulatory readiness necessary to secure and sustain market access.

4.2 Policy and Industry Implications

The implications of these findings extend beyond individual firms and have relevance for policymakers, industry leaders, trade organizations, and economic development agencies. If regulatory barriers continue to restrict SME participation in global markets, the United States risks underutilizing a significant source of innovation, export growth, and technological leadership.

A key priority should be the development of affordable compliance infrastructure capable of supporting SMEs throughout the export process. Regulatory expertise, customs guidance, market-access intelligence, and compliance management services remain inaccessible for many smaller firms because of cost and resource constraints. Expanding access to these capabilities could substantially reduce barriers to international expansion and improve export outcomes.

Equally important is the need to incorporate regulatory market-entry planning into broader export and commercialization strategies. Regulatory readiness should no longer be treated as a secondary administrative consideration addressed after product development is complete. Instead, it should be integrated into early-stage business planning, market selection decisions, product design considerations, and international growth strategies. Organizations that proactively address regulatory requirements are likely to experience fewer delays, lower compliance costs, and greater success in foreign markets.

Government agencies, industry associations, academic institutions, and private-sector stakeholders all have important roles to play in strengthening regulatory preparedness among SMEs. Collaborative efforts that improve access to regulatory knowledge and compliance resources may help create a more competitive and resilient export ecosystem.

4.3 Future Direction

Looking ahead, there is a compelling need to recognize regulatory market entry strategy as a distinct strategic discipline within international business, trade, and pharmaceutical commercialization. Just as organizations invest in research and development, marketing, and supply chain management, they must also develop structured capabilities dedicated to regulatory intelligence, compliance planning, HS classification management, and market-access strategy.

Future efforts should focus on developing scalable compliance solutions specifically designed to address the needs of pharmaceutical and biomedical SMEs. Advances in digital compliance technologies, regulatory intelligence platforms, automated classification systems, and shared compliance services offer promising opportunities to reduce costs while improving export readiness. In addition, targeted policy interventions and public-private partnerships may help bridge the compliance infrastructure gap that currently disadvantages smaller firms.

Ultimately, strengthening regulatory market-entry capabilities among pharmaceutical and biomedical SMEs is not merely an issue of business efficiency. It

is an investment in innovation commercialization, export competitiveness, economic resilience, and national strategic capacity. Ensuring that innovative products can successfully reach global markets will be essential for maintaining U.S. leadership within the increasingly competitive global life sciences economy.

The challenge facing pharmaceutical and biomedical SMEs is therefore clear: the products are ready, but the pathway to global markets remains obstructed. Addressing that challenge will require a fundamental shift in how regulatory market entry is understood, supported, and integrated into export strategy. Only then can the full commercial and societal value of U.S. biomedical innovation be realized on a global scale.

REFERENCES

[1] Junaid SB, Imam AA, Balogun AO, De Silva LC, Surakat YA, Kumar G, et al. Recent Advancements in Emerging Technologies for Healthcare Management Systems: A Survey. Healthcare (Basel). 2022 Oct 3;10(10):1940. doi:10.3390/healthcare10101940 PubMed PMID: 36292387; PubMed Central PMCID: PMC9601636.

[2] Peralta G, Sánchez B. Driving health transformation: big pharma's innovation labs revolution. Health Res Policy Syst. 2025 Oct 23; 23:138. doi:10.1186/s12961-025-01415-8 PubMed PMID: 41131604; PubMed Central PMCID: PMC12551358.

[3] Tawfik EA, Tawfik AF, Alajmi AM, Badr MY, Al-jedai A, Almozain NH, et al. Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia. Saudi Pharm J. 2022 Jan;30(1):28–38. doi: 10.1016/j.jsps.2021.12.002 PubMed PMID: 35145343; PubMed Central PMCID: PMC8802089.

[4] Li L, Li D, Goerzen A, Shi W (Stone). What and how do SMEs gain by going international? A longitudinal investigation of financial and intellectual resource growth. Journal of World Business. 2018 Dec 1;53(6):817–34. doi: 10.1016/j.jwb.2018.07.001

[5] Martins FS, Kollipara S, Sivadasu P, Yu M, Severino P, Souto E. The Innovation Paradox in Emerging Pharmaceutical Markets: Barriers and Opportunities for Sustainable Development. Pharm Res. 2025 Jun;42(6):1047–58. doi:10.1007/s11095-025-03856-w PubMed PMID: 40442394.

[6] Phan TH, Stachuletz R, Nguyen HTH. Export Decision and Credit Constraints under Institution Obstacles. Sustainability. 2022 May 6;14(9). doi:10.3390/su14095638

[7] Morton WA. Regulatory pathways to the market: an overview. Artif Organs. 1982 Nov;6(4):463–9. doi:10.1111/j.1525-1594. 1982.tb04146.x PubMed PMID: 6762190.

[8] Iheanachor N, Umukoro IO, David-West O. The role of product development practices on new product performance: Evidence from Nigeria's financial services providers. Technol Forecast Soc Change. 2021 Mar; 164:120470. doi: 10.1016/j.techfore.2020.120470 PubMed PMID: 33664533; PubMed Central PMCID: PMC7893682.

[9] Dangy-Caye A, Mousset A, Kermad A, Bouché-Bazerolle L, Bujar M, De Lucia ML, et al. Harmonizing health: a global analysis of pharmaceutical regulatory activities by international regulatory organizations. Front Med (Lausanne). 2025 Sep 23; 12:1636269. doi:10.3389/fmed.2025.1636269 PubMed PMID: 41064519; PubMed Central PMCID: PMC12500574.

[10] Fonseca EM da, Shadlen KC, Achcar H de M. Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions. Research Policy. 2023 May 1;52(4):104739. doi: 10.1016/j.respol.2023.104739

[11] Liu J, Zhu H, Wang G. Multiple Pathways to Internationalization Performance in Chinese Plant-Based Food Enterprises: A Configurational Analysis Using fsQCA. Sustainability. 2026 Jun 8;18(12). doi:10.3390/su18125915

[12] Achmad F, Wiratmadja II. Organizational performance and competitive advantage in SMEs: The role of green innovation and knowledge management. Journal of Open

Innovation: Technology, Market, and Complexity. 2025 Jun 1;11(2):100532. doi: 10.1016/j.joitmc.2025.100532

[13] Umaru OT, Adeyemi AS, Aderonmu O, Bhangu BS, Dhaliwal HS, Lim H, et al. Global Pharmaceutical Regulation: Comparative Frameworks and Operations. Pharmacy (Basel). 2026 Mar 18;14(2):50. doi:10.3390/pharmacy14020050 PubMed PMID: 41874058; PubMed Central PMCID: PMC13010624.

[14] TRS 1033 - Annex 10: Good reliance practices in the regulation of medical products: high level principles and considerations [Internet]. [cited 2026 Jun 10]. Available from: https://www.who.int/publications/m/item/annex-10-trs-1033

[15] Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries – perceptions and experiences of pharmaceutical companies in South Africa. South Med Rev. 2012 Jul 23;5(1):31–7. PubMed PMID: 23093897; PubMed Central PMCID: PMC3471191.

[16] Vieira D, Duarte J, Vieira P, Gonçalves MBS, Figueiras A, Lohani A, et al. Regulation and Safety of Cosmetics: Pre- and Post-Market Considerations for Adverse Events and Environmental Impacts. Cosmetics. 2024 Oct 23;11(6). doi:10.3390/cosmetics11060184

[17] Al Azawei A, Loughrey K, Surim K, Connolly ME, Naughton BD. The management of good manufacturing practice (GMP) inspections: a scoping review of the evidence. Front Med (Lausanne). 12:1687864. doi:10.3389/fmed.2025.1687864 PubMed PMID: 41306493; PubMed Central PMCID: PMC12645793.

[18] Reis ME, Bettencourt A, Ribeiro HM. The regulatory challenges of innovative customized combination products. Front Med (Lausanne). 2022 Jul 22; 9:821094. doi:10.3389/fmed.2022.821094 PubMed PMID: 35935795; PubMed Central PMCID: PMC9354569.

[19] Karklina-Admine S, Cevers A, Kovalenko A, Auzins A. Challenges for Customs Risk Management Today: A Literature Review. Journal of Risk and Financial Management. 2024 Jul 24;17(8). doi:10.3390/jrfm17080321

[20] Hassen HK, Mekasha YT, Tegegne AA, Ozalp Y. A narrative review on problems in product quality, regulatory system constraints, and the concept of quality by design as a solution for quality assurance of African medicines. Front Med (Lausanne). 2024 Oct 3; 11:1472495. doi:10.3389/fmed.2024.1472495 PubMed PMID: 39421861; PubMed Central PMCID: PMC11484627.

[21] Nwoke J. Regulatory Compliance and Risk Management in Pharmaceuticals and Healthcare. International Journal of Health Sciences. 2024 Sep 8;7(6):60–88. doi:10.47941/ijhs.2223

[22] Drinkwater S, Robinson C. The impact of customs and trade regulations on the operations of African firms. Journal of Business Research. 2023 Oct 1; 165:114046. doi: 10.1016/j.jbusres.2023.114046

[23] Bui AT, Pham TP, Pham LC, Ta TKV. Legal and financial constraints and firm growth: small and medium enterprises (SMEs) versus large enterprises. Heliyon. 2021 Dec 10;7(12): e08576. doi: 10.1016/j.heliyon. 2021.e08576 PubMed PMID: 34977406; PubMed Central PMCID: PMC8683731.

[24] Akang AU (mnim). REGULATORY COMPLIANCE AND ACCESS TO FINANCE: IMPLICATIONS FOR BUSINESS GROWTH IN DEVELOPING ECONOMIES. Sciental Journal of Education Humanities and Social Sciences. 2023;1(2):8–23. doi: 10.62536/sjehss.2023.v1.i2.pp8-23

[25] Kianpour M, Raza S. More than malware: unmasking the hidden risk of cybersecurity regulations. Int Cybersecur Law Rev. 2024 Mar 1;5(1):169–212. doi:10.1365/s43439-024-00111-7

[26] Mentzelou K, Chountalas PT, Kitsios FC, Magoutas AI, Dasaklis TK. Identifying and Modeling Barriers to Compliance with the NIS2 Directive: A DEMATEL Approach. Journal of Cybersecurity and Privacy. 2025 Nov 6;5(4). doi:10.3390/jcp5040097

[27] Pihwal K, Pawar N, Aamir S, Alam MS, Rathee V. A Comprehensive Review of Regulatory Requirements and Registration Process of Pharmaceutical Drug Products in CIS Countries. Applied Clinical Research, Clinical Trials and Regulatory Affairs. 7(3):162–76. doi:10.2174/2213476X07666200708105237

[28] Dinçkol D, Ozcan P, Zachariadis M. Regulatory standards and consequences for industry architecture: The case of UK Open Banking. Research Policy. 2023 Jul 1;52(6):104760. doi: 10.1016/j.respol.2023.104760

[29] Kgakatsi M, Galeboe OP, Molelekwa KK, Thango BA. The Impact of Big Data on SME Performance: A Systematic Review. Businesses. 2024 Nov 13;4(4):632–95. doi:10.3390/businesses4040038

[30] Mubarak Z, Abbas N, Hashmi FK, Shahbaz H, Bukhari NI. Industrial prospects on regulatory gaps and barriers in pharmaceutical exports and their counteraction: Local experiential with global implication. PLoS One. 2024 Jul 19;19(7): e0305989. doi: 10.1371/journal.pone.0305989 PubMed PMID: 39028685; PubMed Central PMCID: PMC11259304.

[31] Adomako S, Tran MD. Innovating against the odds? The impact of regulatory challenges on technology commercialization and product innovation performance. Technology in Society. 2026 Apr 1; 85:103214. doi: 10.1016/j.techsoc.2026.103214

[32] Alshahrani MA, Salam MA. The Role of Supply Chain Resilience on SMEs' Performance: The Case of an Emerging Economy. Logistics. 2022 Jul 10;6(3). doi:10.3390/logistics6030047

[33] Kiani Mavi R, Kiani Mavi N, Hosseini Shekarabi SA, Pepper's M, Arisian S. Supply Chain Resilience: A Common Weights Efficiency Analysis with Non-discretionary and Non-controllable Inputs. Glob J Flex Syst Manag. 2023 Dec 1;24(1):77–99. doi:10.1007/s40171-024-00380-5

[34] Prasanna R, Jayasundara J, Naradda Gamage SK, Ekanayake E, Rajapakshe P, Abeyrathne G. Sustainability of SMEs in the Competition: A Systemic Review on Technological Challenges and SME Performance. Journal of Open Innovation: Technology, Market, and Complexity. 2019 Dec 1;5(4):100. doi:10.3390/joitmc5040100

[35] Apooyin A. Risk management and compliance in a Globalized Economy: Navigating Regulatory Challenges and Strategic Adaptations. International Journal of Science and Research Archive. 2025;15(1):985–97. doi:10.30574/ijsra.2025.15.1.1098

[36] Burugulla JKR. Enhancing Regulatory Compliance in Finance through Big Data Analytics and AI Automation. Universal Journal of Finance and Economics. 2020 Dec;1(1):1–20. doi:10.31586/ujfe.2020.1335

[37] Muppalla A, Maddi BD, Maddi NV. Artificial Intelligence in Regulatory Compliance: Transforming Pharmaceutical and Healthcare Documentation. International Journal of Drug Regulatory Affairs. 2025 Jun 15;13(2):73–80. doi:10.22270/ijdra. v13i2.764

[38] Keelson SA, Cúg J, Amoah J, Petráková Z, Addo JO, Jibril AB. The Influence of Market Competition on SMEs' Performance in Emerging Economies: Does Process Innovation Moderate the Relationship? Economies. 2024 Oct 21;12(11). doi:10.3390/economies12110282

[39] Jørgensen BN, Ma ZG. Impact of EU Regulations on AI Adoption in Smart City Solutions: A Review of Regulatory Barriers, Technological Challenges, and Societal Benefits. Information. 2025 Jul 2;16(7). doi:10.3390/info16070568

[40] Sitisara S, Jinarat S, Ngamsaard W, Suthikarnnarunai N. Revolutionizing Harmonized System (HS) Code Search with Semantic Search and Word Embeddings: Empowering Trade Classifications. Forum for Linguistic Studies. 2025 Sep 25;7(10):356–71. doi:10.30564/fls. v7i10.10822

[41] Gunningham N. Regulating Small and Medium Sized Enterprises. J Environmental Law. 2002 Jan 1;14(1):3–32. doi:10.1093/jel/14.1.3

[42] Khiewngamdee C, Chanaim S. The Role of Institutional and Innovation Ecosystem in Moderating the Impact of Green Practices on

Export Performance: Evidence from European Countries. Sustainability. 2025 Oct 14;17(20). doi:10.3390/su17209146

[43] Limited (PPL) PP. Regulatory Challenges in Pharma Development Across US, UK & Canada [Internet]. [cited 2026 Jun 10]. Available from: https://www.piramalpharma.com/news-and-media/blogs/regulatory-challenges-in-pharma-development-across-us-uk-canada

[44] Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: A narrative review. Heliyon. 2024 Feb 15;10(4):e26297. doi: 10.1016/j.heliyon. 2024.e26297 PubMed PMID: 38384518; PubMed Central PMCID: PMC10879008.

[45] Verbeke A. The future of international business strategy research. International Business Review. 2026 Aug 1;35(4):102596. doi: 10.1016/j.ibusrev.2026.102596